β-Thalassemia
Top Cited Papers
- 15 September 2005
- journal article
- review article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 353 (11), 1135-1146
- https://doi.org/10.1056/nejmra050436
Abstract
β-Thalassemia, which is caused by a decrease in the production of β-globin chains, affects multiple organs and is associated with considerable morbidity and mortality. Lifelong care is required, and the costs of proper treatment are substantial. This review discusses current approaches to the management of β-thalassemia.Keywords
This publication has 84 references indexed in Scilit:
- Complications of β-thalassemia major in North AmericaBlood, 2004
- Unrelated Umbilical Cord Blood Transplantation for an Infant With ??-Thalassemia MajorJournal of Pediatric Hematology/Oncology, 2004
- GROWTH AND ENDOCRINE FUNCTION FOLLOWING BONE MARROW TRANSPLANTATION FOR THALASSEMIA MAJORPediatric Hematology and Oncology, 2004
- Role of deferiprone in chelation therapy for transfusional iron overloadBlood, 2003
- Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2003
- High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNABlood, 2003
- Development of virus vectors for gene therapy of β chain hemoglobinopathies: flanking with a chromatin insulator reduces γ-globin gene silencing in vivoBlood, 2002
- Full chimerism in nonmyeloablative stem cell transplantation in a β-thalassemia major patient (class 3 Lucarelli)Bone Marrow Transplantation, 2002
- Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in β-thalassemia intermedia patientsFree Radical Research, 2001
- Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterThe Lancet, 2000